-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Read more: Beyond the Snapshot: Continuous physiologic monitoring in clinical trialsVivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.
More in Latest News
In Conversation With
-
Scaling impact without leaving medicine
Dr Bryony Henderson, a former frontline GP, on reframing your career, overcoming guilt, and finding purpose at scale.
-
ECCO26 data reinforce long-term durability and real-world impact of AbbVie’s IBD portfolio
Real-world data and three-year trial results show sustained remission and symptom control with Skyrizi and Rinvoq.
-
Why Pharma can’t ignore friendshoring in supply chain
Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.
-
Inside Immunai’s plan to map the entire immune system
Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.
-
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
AI and Technology
Latest news
-
How human organs are rewriting the rules of drug development
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.
Expert Interviews
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.
Sustainability In Pharma
Latest news
-
Building sustainable medical products: Polaroid exec on innovation and challenges
Head of Product at Polaroid Therapeutics, Paul Saunders, shares his approach to embedding sustainability in healthcare innovation.
Company Analysis
-
CVS Health makes headway in becoming environmentally sustainable
The progress and trend in the reduction of the GHG emissions and GHG emission intensity over the last six years reflect that CVS Health’s progress towards the goal of Net-zero by 2050 is on track.
Looking to read an in-depth analysis of Sustainability, AI, and the Latest Technology in healthcare sector
You can access members-only exclusive content for as little as $4.2 per month.
More Posts
-
Seamflow secures $4.5m to deploy AI for testing and certification bottlenecks
London-based AI startup raises seed funding to tackle certification delays in medical devices and industrial sectors.
-
RevealDx wins FDA clearance for lung nodule assessment software
New AI software aims to help radiologists assess lung nodule cancer risk and improve early detection.
-
Inside Immunai’s plan to map the entire immune system
Immunai CEO Noam Solomon details four pivotal studies shaping the future of immunology and oncology research, as part of the ‘Grand Collaboration’.
-
How ambient AI is capturing healthcare’s unheard data
The Sciensus team discusses how ambient AI captures patient sentiment to augment nurses, personalise care, and help keep patients healthier at home.
-
CAR T enters a new era of in vivo reprogramming of T cells
Vyriad’s Luke Russell explores the technical and economic promise of in vivo CAR T-cell therapies.
-
Building resilient pharmaceutical supply chains in an era of disruption
Kum Ming Woo advises prioritizing supplier quality & availability over cost, emphasizing geographic diversification and stage-appropriate strategies.
-
Hospital of 2026: Local LLMs and AI Are Redefining Healthcare
myTomorrow’s Danny den Hamer identifies two trends for 2026: hospitals adopting local AI/trusted partners, and a rise in certified AI medical devices.
-
Arkin Bio Ventures III: $100 million fund for transformative therapies
Fund lead, Dr. Pini Orbach, talks about the fund targeting oncology, immunology, inflammation, rare diseases, and their aim to be an active partner from day one.
-
Boehringer picks AI imaging tech as co-primary endpoint for IPF trial
Brainomix’s e-Lung AI will provide quantitative imaging biomarkers as a co-primary endpoint in Boehringer Ingelheim’s Phase III DROP-FPF study.
-
VCU researchers win $1.8 million US DoD grant for cancer therapy
The US Department of Defense (DoD) grant funds engineered NK cell therapy for resistant prostate cancer.
-
Becton Dickinson and ten23 partner on wearable injector supply
Partnership will support the supply for Becton, Dickinson and Company’s self-administered therapies with a ready-to-use, scalable platform.
-
The New Gold Rush: High-stakes race for multi-cancer blood tests
Abbott’s $23 billion Exact Sciences buyout sets stage for high-stakes MCED battle, Elena Meng talks about the major players in the sector and hurdles.
-
Examining the growing delays in clinical trial start-up
ICON exec discusses the increasing timeframe from site selection to full activation, including the issues contributing to the delay and measures to address them.